| |
Bivariate
|
Adjusted
|
|---|
|
Characteristics
|
HR (95% CI)
|
p-value
|
aHR (95% CI)
|
p-value
|
|---|
|
Intervention group
|
1.0 (0.5;1.7)
|
0.94
| | |
|
Male gender
|
2.0 (0.1;4.0)
|
0.05
| | |
|
Age <35 years
|
0.7 (0.4;1.4)
|
0.37
| | |
|
Severe HIV (clinical stage 3 or 4)
|
1.2 (0.6;2.1)
|
0.59
| | |
|
History of IDU
|
1.9 (1.0;3.3)
|
0.04
| | |
|
ART-non-naïve status
|
4.8 (2.4;9.4)
|
<0.01
|
7.0 (3.3–14.7)
|
<0.01
|
|
TB history
|
1.6 (0.8;3.2)
|
0.15
| | |
|
VL at baseline ≥100,000 copies/ml
|
1.6 (0.9;2.8)
|
0.13
|
2.3 (1.2–4.3)
|
<0.05
|
|
CD4 at baseline < 100 cells/μl
|
1.4 (0.8;2.5)
|
0.28
| | |
|
Having an HIV-infected family member
|
0.5 (0.3;0.9)
|
0.03
| | |
|
From Ha long OPC
|
1.0 (0.6;1.8)
|
0.91
| | |
|
History of OIs
|
0.5 (0.2;1.0)
|
0.06
| | |
|
Changed ART regimen
|
1.1 (0.5;−2.0)
|
0.85
| | |
|
Incomplete adherence
|
2.4 (0.9;6.7)
|
0.09
|
3.1 (1.1–8.9)
|
<0.05
|
- OIs opportunistic infections, VL viral load, IDU Injecting drug use, TB tuberculosis, ART Antiretroviral therapy, OPC outpatient clinic, HR Hazard Ratio, aHR adjusted Hazard Ratio
- The boldface indicates significant (p<0,05) result
